TrialScope Welcomes Alexion to Its Growing Clinical Trial Disclosure Community
Alexion joins the ranks of other industry leaders that rely on TrialScope Disclose™ to help manage global clinical trial disclosure.
JERSEY CITY, N.J., March 4, 2021 /PRNewswire-PRWeb/ -- TrialScope, the global leader in clinical trial disclosure and transparency technology, recently added Alexion to its rapidly expanding roster of customers.
Alexion joins the ranks of other industry leaders that rely on TrialScope Disclose™ to help manage global clinical trial disclosure. TrialScope's customers run the gamut from specialized biotechs to global pharmaceutical companies. Collectively, TrialScope customers are responsible for more than 40 percent of all industry trials on ClinicalTrials.gov and the EU-CTR. More than 12,000 users manage 67,000-plus trials using TrialScope technology.
In order to keep the public informed and trial participants engaged, Alexion also will post study results on the Trial Results Summaries portal, hosted by TrialScope. The unbranded website is in keeping with best practices for plain-language summaries (PLS), which dictate that study results be presented in a non-commercial, easily understood format. Catering to a global audience, the portal is enhancing its content to include 45 languages.
Alexion was seeking a complete, robust solution to manage clinical trial transparency and registry posting, one that could accommodate the company's anticipated growth. The TrialScope Disclose platform, which syncs data across forms and registries, automates submission to ClinicalTrials.gov and supports an additional 36 global clinical trial registries.
"TrialScope was the obvious choice, for both its intuitive technology and the deep knowledge of its staff," said Jim Armbrust, Esq., Alexion Director, Clinical Trial Transparency and Disclosure. "At Alexion, we take clinical trial disclosure compliance and trial transparency very seriously. I think our decision to work with TrialScope and its subject-matter experts is a reflection of that."
"We salute Alexion's continued efforts to improve the lives of patients with rare diseases," said TrialScope Chief Commercial Officer Chris Venezia. "Alexion is not merely a customer but a true partner. We are proud to work alongside the Alexion team to help promote clinical trial transparency and accessibility."
About TrialScope
TrialScope gives your clinical trial data superpowers™. We make centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 17 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment. To learn more, visit TrialScope.com.
TrialScope was acquired by Informa Pharma Intelligence in 2020, combining its powerful technology for disclosure, transparency and recruitment with leading brands, data and solutions for the clinical trials and broader pharmaceutical and biomedical industry.
About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Medtrack™, Biomedtracker™, Scrip™, Pink Sheet™ In Vivo™ and most recently TrialScope—to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
About Alexion
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
Media Contact
Darcy Grabenstein, TrialScope, +1 929-278-5784, [email protected]
SOURCE TrialScope
Share this article